drugset / Trial / NCT06620003
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Phase 2
Active not recruiting
200 enrolled
Albert B. Sabin Vaccine Institute
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Timeline
- Start
- 2025-04-14
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | cAd3-Marburg Vaccine | Vaccine | 1e+11 unknown | Intramuscular |